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1. INTRODUCTION
In 1992, autotaxin (ATX or ENPP2) was isolated as an
autocrine motility factor from melanoma cells.
1 The ∼120 kDa
glycoprotein ATX belongs to a small family named
ectonucleotide pyrophosphatase and phosphodiesterase
(ENPP), which consists of seven family members.
2 ATX is
the only ENPP family member with lysophospholipase D
(lysoPLD) activity and is responsible for the hydrolysis of
lysophosphatidylcholine (LPC) to produce the bioactive lipid
lysophosphatidic acid (LPA) (Scheme 1).
3,4 LPA acts on
specific G-protein-coupled receptors and thereby stimulates the
migration, proliferation, and survival of many cell types.
5,6 ATX
is produced in various tissues and is the major LPA-producing
enzyme in the circulation. After biosynthesis by ATX, LPA is
subject to degradation by membrane-bound lipid phosphate
phosphatases (LPPs).
7,8
ATX is essential for vascular development
9,10 and is found
overexpressed in various human cancers.
11 Forced over-
expression of ATX or individual LPA receptors promotes
tumor progression in mouse models,
12−15 while LPA receptor
deficiency protects from colon carcinogenesis.
16 In addition to
its role in cancer, ATX−LPA signaling has been implicated in
lymphocyte homing and (chronic) inflammation,
17 fibrotic
diseases,
18,19 thrombosis,
20 and cholestatic pruritus.
21 Given its
role in human disease, the ATX−LPA axis is an interesting
target for therapy that deserves significant attention. The fact
that ATX is an extracellular enzyme makes it even more
attractive as a drug target.
2. ATX PROTEIN
Alternative splicing of the ATX gene (enpp2) results in three
distinct isoforms (α, β,a n dγ) which are differentially
expressed.
22,23 ATX β (863 aa) is the best studied isoform
and is identical to plasma lysoPLD. ATX β is mainly expressed
in peripheral tissues, whereas lower expression levels are
observed in the central nervous system. In contrast, the ATX γ
(889 aa) isoform is predominantly expressed in the central
nervous system. ATX α (915 aa), the original melanoma-
derived isoform, exhibits the lowest expression levels in both
the central nervous system and peripheral tissues. The ATX α
isoform contains a nonspecific protease cleavage site that is not
present in the other isoforms.
22 All the three ATX isoforms
exhibit similar catalytic activities in vitro.
22
ATX is produced initially as a pre-proenzyme that has an N-
terminal signal peptide required for secretion.
24 This signal
peptide is removed by a signal peptidase, and ATX is
subsequently cleaved by proprotein convertases (PCs) like
furin.
24 The removal of an N-terminal octapeptide in ATX by
PCs is associated with an enhancement of ATX activity.
24 The
proteolytically processed ATX is secreted and consists of
several domains. Starting from its N-terminus, ATX has two
somatomedin B (SMB)-like domains, a central catalytic
phosphodiesterase (PDE) domain, and an inactive nuclease-
like domain, as displayed in Scheme 1. The hydrolytic activity
of ATX predominantly originates from a threonine residue and
two zinc ions in the ATX active site located in the PDE
domain.
25 Extending from the ATX active site there is a
hydrophobic pocket where the alkyl chain of its lipid substrates
binds.
26
3. NATURAL SUBSTRATES OF ATX
Next to LPC hydrolysis, ATX is also capable of hydrolyzing
sphingosylphosphorylcholine (SPC, Figure 1) into sphingosine
1-phosphate (S1P).
27 S1P has signaling properties comparable
to those of LPA while acting on S1P receptors.
28−30 It is
however doubtful how relevant the contribution of ATX is to
S1P production in vivo. S1P is thought to originate mainly from
the phosphorylation of sphingosine by sphingosine kinases,
rather than through SPC hydrolysis by ATX.
31
Next to recognizing the lipids LPC and SPC as substrates,
ATX can also hydrolyze nucleotides, like its family members
ENPP1 and ENPP3. In vitro established nucleotide and
nucleotide-derived substrates of ATX consist of adenosine-5′-
triphosphate (ATP), diadenosine polyphosphates (ApnA),
uridine diphosphate glucose (UDP-glucose), nicotinamide
adenine dinucleotide (NAD+), and 3′-phosphoadenosine-5′-
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2 The physiological relevance of
ATX-mediated hydrolysis of these nucleotide substrates is still
unclear.
4. ASSAYS TO STUDY ATX ACTIVITY
In the search for inhibitors, appropriate in vitro assays are
required to monitor the activity of the enzyme of interest. Over
the last 10 years various assays have been developed and used
to study the activity of ATX. ATX assays can roughly be divided
in two classes depending on the kind of ATX substrate used for
the activity measurement. The first class uses the physiological
ATX substrate LPC and the second class uses unnatural ATX
substrates.
4.1. LPC-Based Assays
As depicted in Table 1, ATX hydrolyzes LPC into LPA and
choline. Both products can be used to measure ATX activity.
When a 14C label is introduced in the lipid tail of LPC, ATX
activity can be measured by radiometry.
32,33 When radiolabeled
LPC is hydrolyzed by ATX, the produced LPA contains this
radiolabel. After lipid extraction of the ATX−LPC incubation
mixture and separation of LPC and LPA using thin layer
chromatography (TLC),
4 the activity of ATX can be quantified
from the 14C-LPA produced. Although this classical method is
robust and very sensitive, it is not very suitable for high-
throughput screening (HTS).
Another way to measure the formation of LPA is by using
liquid chromatography−tandem mass spectrometry (LC−MS/
MS).
34,35 From an ATX incubation mixture, LPC and LPA are
separated by LC and detected by tandem MS. This method is
very sensitive and suitable to detect naturally occurring LPA in
biological fluids (i.e., plasma).
34−36
ATX activity can also be measured by the detection of
choline.
4,37 When choline is released from the ATX-mediated
LPC hydrolysis, it can be converted by choline oxidase into
betaine (trimethylglycine) and hydrogen peroxide. Subse-
quently, hydrogen peroxide is used by horseradish peroxidase
(HRP) to convert a coloring substrate into its oxidized
chromophoric state. Different HRP coloring substrates can be
used like 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS), homovanillic acid (HVA), or Amplex red. ABTS can
be detected using absorbance while HVA and Amplex red are
detected by fluorescence.
36,38,39 The throughput of this assay is
high and suitable for HTS screening.
A danger of the latter assay is that small molecules that do
not inhibit ATX may interfere with the readout by inhibiting
the enzymes (HRP or choline oxidase) used in the coloring
reaction, which will result in false positives. Another possibility
that could result in false positives is that reactive compounds
tested in this assay can react with the coloring agent or
hydrogen peroxide that is generated during that coloring
reaction. Incubating molecules that are active in this assay with
only choline and subsequently adding the coloring reagents
should reveal if these molecules are interfering with the assay
readout.
38
4.2. Unnatural ATX Substrate-Based Assays
As a member of the ENPP family, ATX also hydrolyzes
nucleotides. Therefore, the nucleotide thymidine 5′-mono-
phosphate p-nitrophenyl ester (pNP-TMP) can be used as an
ATX substrate (Table 1).
3,25 Upon hydrolysis of pNP-TMP by
ATX, 4-nitrophenol is released, which has an absorbance at 405
nm and is detectable by colorimetry.
The same product is formed when bis(p-nitrophenyl)
phosphate (bis-pNPP) is hydrolyzed by ATX (Table 1).
33,38
Bis-pNPP is a cheap ATX substrate that provides a direct
readout.
Another artificial ATX substrate is CPF4, which has a similar
core structure as bis-pNPP. In CPF4 the two nitro groups of
bis-pNPP are replaced by coumarin and fluorescein (Table
1).
33,40 When the coumarin donor group in CPF4 is excited,
Förster fluorescence resonance energy transfer (FRET)
between coumarin and the fluorescein acceptor occurs. After
hydrolysis the FRET pair is separated and FRET is lost,
Scheme 1. ATX Is Responsible for Hydrolyzing LPC into
LPA in an Extracellular Environment
a
aThis reaction is catalyzed by a threonine residue and two zinc ions
present in the ATX active site. LPA activates specific G-protein-
coupled receptors stimulating migration, proliferation, and survival of
cells. ATX is displayed as a cartoon representation of an ATX crystal
structure (PDB ID 2XR9) with the SMB domains in purple, the PDE
domain in green, and the nuclease-like domain in blue.
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was originally developed for phosphodiesterase I,
40 it provides a
very sensitive ATX activity sensor as well.
33
FS3 is another synthetic ATX substrate that is based on LPC
(Table 1).
41 In this substrate a dabcyl moiety, a quencher of
fluorescein, is connected via a lipid backbone to fluorescein.
The fluorescein moiety in FS3 is quenched by the dabcyl
moiety and becomes fluorescent when FS3 is hydrolyzed by
ATX.
A common advantage of the above-mentioned assays is that
they provide a realtime readout, allowing direct kinetic studies
of ATX activity.
4.3. ATX Activity-Based Probe
A first generation ATX activity-based probe (ATX-ABP) has
recently been reported (Table 1).
42 This probe makes use of
the activity of ATX to label ATX covalently. Upon the
hydrolysis of the phosphodiester bond in ATX-ABP, the
released intermediate undergoes an 1,6-elimination of a fluoride
atom (Scheme 2). This generates a reactive quinone methide
species that traps nearby nucleophiles in the ATX active site,
resulting in covalent labeling of ATX with a fluorescent Cy5
dye in an activity-dependent manner. This ATX-ABP is able to
label all the three known ATX isoforms.
42 In addition, ATX-
ABP can label ATX in human plasma; however, an additional
affinity-purifying step with an anti-ATX monoclonal antibody is
required to make labeled ATX detectable. Further development
of these types of probes could turn them into diagnostic
reagents to monitor ATX activity in complex samples such as
body fluids.
5. INHIBITORY EFFECT OF METAL CHELATORS ON
ATX ACTIVITY
L-Histidine has been reported as the first in vitro “ATX
inhibitor” with millimolar IC50 values for ATX using LPC or
pNP-TMP as assay substrate.
43 It acts by scavenging metal ions
in solution, such as zinc, which are essential for ATX activity. In
addition, other metal chelating agents such as ethylenediami-
netetraacetic acid (EDTA) and 1,10-phenanthroline also have
an inhibitory effect on ATX activity.
43
6. LIPID AND LIPID-BASED INHIBITORS OF ATX
A distinct class of ATX inhibitors is based on lipids. The
discovery of product inhibition of ATX by LPA and S1P
33
Figure 1. Identified natural substrates of ATX.
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2).
One class of lipid-based inhibitors includes thiophos-
phates.
44−46 An example of this class is thiophosphate 3
(IC50 = 0.6 μM, bis-pNPP) depicted in Table 2. The reported
thiophosphates also act as agonists or antagonists for LPA1−3
receptors.
44−46 A general danger of lipid-based ATX inhibitors
is that they may act on downstream LPA/S1P receptors due to
their structural similarity with LPA and S1P.
There is also a class of ATX inhibitors based on cyclic
phosphatidic acid (cPA) that is a naturally occurring analog of
LPA where the sn-2 hydroxy group forms a five-membered ring
with the sn-3 phosphate.
47,48 cPA analog 4 (Table 2, IC50 =
0.14 μM, bis-pNPP) has no significant agonist activity at LPA
receptors. Recently, a sulfur analogue of cPA, 3-O-thia-cPA (5),
has been reported as an ATX inhibitor (Table 2).
49
Another class of lipid-based ATX inhibitors is based on α-
bromomethylene phosphonates like BrP-LPA (6, Table 2).
50,51
In addition, phosphonate 6 acts as a pan-LPA1−4 receptor
antagonist. α-Bromobenzyl phosphonates are well-known
protein tyrosine phosphatase inhibitors that target the active
site covalently.
52 Whether phosphonate 6 inhibits ATX in a
covalent manner is unknown.
An inhibitor that is expected to bind ATX covalently is
flouromethylphenyl phosphate 7 (Table 2).
53 The binding
mechanism of 7 with ATX is postulated to be the same as for
ATX-ABP, as depicted in Scheme 2. Inhibitor 7 shows time-
dependent inhibition of ATX.
Table 1. Substrates for ATX-Activity Assays
aLPA can be detected by radiometry or mass spectrometry. Choline can be detected in a two-step enzymatic colorimetric reaction.
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2) inhibits ATX with a Ki of 0.2 μM using pNP-TMP as an
ATX assay substrate.
54,55 FTY720-P is a synthetic analogue of
S1P and acts as an S1P1 receptor antagonist (EC50 = 5 nM)
55
that activates this receptor, causing its internalization and
subsequent polyubiquitination, leading to proteasomal degra-
dation of the S1P1 receptor. This results in the unresponsive-
ness of lymphocytes to S1P.
56
Potencies of the previously described lipid-based inhibitors
all have been determined in assays using unnatural ATX
substrates (bis-pNPP, pNP-TMP, CPF4, and FS3) as reporter
molecules. Therefore, it is difficult to compare potencies of
distinct inhibitors and their effect on LPC hydrolysis. Using
assays based on LPC hydrolysis gives a better indication
whether ATX inhibitors could have an in vivo effect on LPA
production by ATX. The most potent (IC50 = 5.6 nM, LPC)
lipid-based inhibitor measured in an LPC hydrolysis assay is
S32826 (9, Table 2).
39,57,58 This phosphonate inhibitor is a
result of screening 13 000 small molecules for their ability to
inhibit ATX. Unfortunately, the poor in vivo stability and/or
bioavailability of the compound did not permit further use in
animal models.
A last lipid-like inhibitor class is based on a tyrosine building
block, and an example of this class is inhibitor 10, which has a
micromolar potency (Ki = 1.0 μM, LPC, Table 2).
59−61
A frequently observed phenomenon for ATX inhibitors is
their incapability to fully inhibit ATX. Examples are inhibitors
3, 4, and 9 depicted in Table 2 that have residual ATX activity
(RA) for ATX.
7. SMALL MOLECULE INHIBITORS OF ATX
Since 2008, many small molecule inhibitors have been reported
in both academic and patent literature (Table 3). The most
potent inhibitor (IC50 = 1.7 nM, LPC) reported to date is PF-
8380 (11).
62,63 Interestingly, this compound reported by
employees of Pfizer
62 is based on an inhibitor described in a
Merck KGaA patent application.
63 Due to the high potency and
favorable pharmacokinetic properties, PF-8380 is a suitable tool
compound for in vivo evaluation of ATX inhibition.
Another very potent ATX inhibitor is the boronic acid
HA155 (12,I C 50 = 5.7 nM, LPC, Table 3).
36,38 This molecule
resulted from screening ∼40000 small molecules followed by
medicinal chemistry efforts on the resulting screening hit. In
the original screening hit, a carboxylic acid moiety was replaced
by a boronic acid moiety, designed to target the threonine
oxygen nucleophile in the ATX active site. HA130,
36,38 a
positional boronic acid isomer of HA155, together with PF-
8380 are the only two inhibitors to date that have been
demonstrated to lower LPA levels in vivo (rat or mice).
Recently, other boronic acid-based inhibitors have been
reported
64 as a result of a structure-based study resulting in E-
HA219 (13, Table 3), a potent inhibitor of ATX (IC50 = 5.3
nM, LPC).
A common feature of the three most potent inhibitors
reported so far (11−13, Table 3) is that they share a long linear
and flexible structure, which is also reflected in the structure of
LPC and LPA. Probably this structural feature helps the
inhibitors to accommodate to the lipid binding site, since they
bind to the ATX active site. Most of the other reported small
molecules inhibitors lack this structural feature.
Several Merck KGaA patent applications claim ATX
inhibitors (15−18) with in vitro potencies between 0.1 and
10 μM (LPC).
65−71 The structural diversity of these inhibitors
is large, as can be judged from Table 3.
Screening a phosphodiesterase targeted inhibitor library
revealed that vinpocetine (19, Table 3), a PDE type 1 inhibitor
(IC50 =8 −50 μM), inhibits ATX with an IC50 value of 122 μM
using LPC as a substrate.
72 In addition, screening a second
library consisting of kinase inhibitors known to target the ATP
binding site in kinases resulted in the discovery of
damnacanthal (20, Table 3), a p56lck tyrosine kinase inhibitor
Scheme 2. Labeling Mechanism of ATX with ATX-ABP
a
aOnly one of the potential labeled products resulting from the labeling is shown.
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aThe first reference corresponds with the displayed structure and the following references refer to similar inhibitor structures.
bRA, residual ATX
activity.
cPI, percentage inhibition.
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LPC).
72
Several ATX screening programs used libraries from the
National Cancer Institute (NCI). This led for example to the
discovery of arsenic acid NSC-48300 (21, Table 3) as ATX
inhibitor, reported by two independent groups.
38,73,74 It is a
competitive inhibitor that could suggest that the arsenic acid
moiety in 21 acts as a nonhydrolyzable phosphate mimic. In
addition, NSC-9616 (22, Table 3) has been identified as ATX
inhibitor from screening an NCI library.
75
The first virtual screen for ATX inhibitors led to the
discovery of H2L-7905958 (23, Table 3).
76 This inhibitor has a
Ki value of 1.9 μM (FS3) for ATX.
77 At the time of this virtual
screen the ATX structure was not resolved. Therefore, the
authors generated a homology model of ATX based on a
Xanthomonas axonopodis pV. citri (Xac) ENPP structure and
used this homology model for virtual screening. Recently, a
follow-up study has been reported describing new analogues of
23.
77
Another ATX inhibitor is bithionol (24, Table 3),
73,74 a
known metal ion chelating molecule like L-histidine and
EDTA.
78 The latter two inhibit ATX by scavenging metal
ions in solution, which are required for ATX activity. However,
inhibitor 24 appears to act directly on ATX and not via metal
chelation, since the Ki value of 24 for ATX is 2 orders of
magnitude lower than the used metal ion concentration.
8. ATX STRUCTURE AND INHIBITOR DESIGN
In 2011 the crystal structure of ATX had been resolved
independently by two groups.
26,79 Aside from the unliganded
ATX structure, structures of ATX with different species of
LPA
26 and the inhibitor HA155 liganded ATX structure
79 have
been reported. Binding of HA155 to the ATX active site is
predominantly driven by hydrophobic interactions and by a
boronic acid moiety binding to the threonine oxygen
nucleophile in the ATX active site (Figure 2B).
79 The latter
binding was predicted because the boronic acid moiety in
HA155 was designed and introduced to target the threonine
oxygen nucleophile in the ATX active site. In addition, the
ATX−HA155 structure showed that one of the boronic acid
hydroxyl moieties is simultaneously tethered by the two zinc
ions in the ATX active site (Figure 2B). Therefore, the boronic
acid moiety not only targets the threonine oxygen nucleophile
but also the two zinc ions that are essential for the catalytic
activity of ATX. Another feature of HA155 binding to the ATX
active site is that its 4-fluorobenzyl moiety binds to the
hydrophobic lipid binding pocket of ATX (Figure 2A),
preventing the alkyl chain of the lipid from binding to this
pocket.
26,79
The ATX structure liganded with HA155 triggered an ATX
structure-based inhibitor design.
64 This study led to E-HA219
(IC50 = 5.3 nM, LPC, Table 3) a hydantoine analogue of
HA155 (IC50 = 5.7 nM, LPC, Table 3). Remarkably, E-HA219
is an E-isomer while HA155 is a Z-isomer. To understand how
E-HA219 binds to ATX, molecular docking experiments were
performed that suggested a binding pose for E-HA219 different
from that of the original binding pose of HA155 or from the Z-
isomer of HA219 for ATX. This study predicted that the 4-
fluorobenzyl moiety in HA155 and E-HA219 binds differently
to the hydrophobic pocket in ATX. This finding may be used to
design new inhibitors that fully exploit the hydrophobic pocket
in ATX, opening further options for inhibitor design.
9. CONCLUDING REMARKS
ATX is an attractive therapeutic target for LPA-related diseases.
In the past decade, many ATX inhibitors have been discovered
and developed, ranging from metal chelators to lipid and lipid-
based inhibitors to small molecule inhibitors. Over the last 3
years many patents on ATX inhibitors have appeared from
pharmaceutical industry and academia emphasizing the interest
on ATX as drug target. Finally, the recently reported crystal
structures of ATX will aid medicinal chemistry efforts to further
develop ATX inhibitors into therapeutic agents.
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NONSTANDARD ABBREVIATIONS
ABTS 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic
acid)
ApnA diadenosine polyphosphates
ATP adenosine-5′-triphosphate
ATX autotaxin
ATX-ABP ATX activity-based probe
bis-pNPP bis(p-nitrophenyl) phosphate
cPA cyclic phosphatidic acid
EDTA ethylenediaminetetraacetic acid
ENPP ectonucleotide pyrophosphatase and phospho-
diesterase
FRET Förster fluorescence resonance energy transfer
HRP horseradish peroxidase
HTS high-throughput screening
HVA homovanillic acid
LC−MS/MS liquid chromatography−tandem mass spectrom-
etry
LPA lysophosphatidic acid
LPC lysophosphatidylcholine
LPP lipid phosphate phosphatases
lysoPLD lysophospholipase D
NAD+ nicotinamide adenine dinucleotide
NCI National Cancer Institute
PC proprotein convertases
pNP-TMP thymidine 5′-monophosphate p-nitrophenyl
ester
S1P sphingosine 1-phosphate
SMB somatomedin B
SPC sphingosylphosphorylcholine
TLC thin layer chromatography
UDP uridine diphosphate
Xac X. axonopodis pV. citri
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